BioCardia (OTCMKTS:BCDA) and NOVOZYMES A/S/S (OTCMKTS:NVZMY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
This table compares BioCardia and NOVOZYMES A/S/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NOVOZYMES A/S/S pays an annual dividend of $0.49 per share and has a dividend yield of 1.1%. BioCardia does not pay a dividend. NOVOZYMES A/S/S pays out 28.0% of its earnings in the form of a dividend.
Volatility and Risk
BioCardia has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500. Comparatively, NOVOZYMES A/S/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Institutional & Insider Ownership
0.1% of BioCardia shares are owned by institutional investors. Comparatively, 0.2% of NOVOZYMES A/S/S shares are owned by institutional investors. 16.9% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for BioCardia and NOVOZYMES A/S/S, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares BioCardia and NOVOZYMES A/S/S’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NOVOZYMES A/S/S||$2.28 billion||5.97||$511.29 million||$1.75||26.20|
NOVOZYMES A/S/S has higher revenue and earnings than BioCardia.
NOVOZYMES A/S/S beats BioCardia on 8 of the 12 factors compared between the two stocks.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trials for the treatment of heart failure and chronic myocardial ischemia. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a bio-therapeutic delivery system. The company is also developing CardiALLO Cell Therapy System, an allogeneic off the shelf mesenchymal stem cell product candidate, which is in Phase II trials for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system and Morph vascular access product line, which provides catheter products. BioCardia, Inc. has a collaboration with CellProThera for clinical trial and marketing of early stem cell therapy for patients following myocardial infarction in Singapore. The company is based in San Carlos, California.
About NOVOZYMES A/S/S
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. The company offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products. It also provides enzymes for baking applications, including freshness, product appearance, dough improvement, etc.; and brewing applications comprising fermentation control, separation and filtration, etc., as well as for use in lactose-free dairy, trans fats removal, etc. in the food and beverages industry. In addition, the company offers enzymes and microorganisms for use in the production of cellulosic ethanol, starch-based ethanol, enzymatic biodiesel, and sugarcane ethanol in the bioenergy industry; and feed enzymes for use in animal feed, probiotics for animal health applications, microbials for aquaculture applications, and other enzymes and microorganisms for plant health and crop yield applications in the agriculture and feed industry. Further, it provides enzymes and microorganisms for use in textile processing, pulp and paper production, leather preparation, pharmaceuticals, and wastewater treatment solutions. The company has a strategic collaboration with Boehringer Ingelheim Animal Health for research and development, production, marketing, and sale of a portfolio of probiotic products. It also has a collaboration agreement with Elanco Animal Health Incorporated. Novozymes A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.